OKYO Pharma announced the activation of the first clinical trial site in the U.S. for its phase 2, multi-center, randomized, double-blinded, placebo-controlled trial, evaluating the efficacy and safety of OK-101 ophthalmic solution in subjects with dry eye disease. First patient first visit is presently expected to occur within the next two weeks.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on OKYO:
- OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
- Notice of General Meeting and Publication of Circular
- OKYO Pharma to delist from London Stock Exchange
- Notice of Intention to Delist From The London Stock Exchange
- OKYO Pharma chairman purchases 11,000 ADS for $1.41
